Taorolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation

被引：0
|
作者：
Bechstein, WO
Neuhaus, P
McMaster, P
Calne, R
Pichlmayr, R
Otto, G
Williams, R
Ericzon, BG
Bismuth, H
机构：
来源：
TRANSPLANTATION PROCEEDINGS | 1996年 / 28卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1008 / 1010
页数：3
相关论文
共 50 条
  • [1] FK 506 as primary immunosuppressive therapy in renal transplantation
    Preston, R
    Ball, S
    Cairns, T
    Contis, J
    Hakim, N
    Palmer, A
    Papalois, V
    Taube, D
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) : 1214 - 1215
  • [2] FK506 for primary and rescue therapy following liver transplantation
    Platz, KP
    Mueller, AR
    Zytowski, M
    Lobeck, H
    Neuhaus, P
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) : 1409 - 1410
  • [3] FK506 as primary immunosuppressive therapy in renal transplantation.
    Preston, R
    Ball, S
    Cairns, T
    Hakim, N
    Palmer, A
    Papalois, V
    Taube, D
    KIDNEY INTERNATIONAL, 1999, 55 (05) : 2093 - 2093
  • [4] RENAL ARTERIOPATHY ASSOCIATED WITH FK-506 THERAPY FOLLOWING LIVER-TRANSPLANTATION
    CONNOLLY, JO
    GANE, E
    HIGGINS, RM
    ODONNELL, PJ
    DEVLIN, J
    SCOBLE, JE
    WILLIAMS, R
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1994, 9 (07) : 834 - 836
  • [5] A COST COMPARISON OF LIVER-TRANSPLANTATION WITH FK-506 OR CYA AS THE PRIMARY IMMUNOSUPPRESSIVE AGENT
    STASCHAK, S
    WAGNER, S
    BLOCK, G
    VANTHIEL, DH
    JAIN, A
    FUNG, J
    TODO, S
    STARZL, TE
    TRANSPLANTATION PROCEEDINGS, 1990, 22 (01) : 47 - 49
  • [6] Different immunosuppressive effects of liposomal FK506 in liver and kidney transplantation
    Ko, S
    Nakajima, Y
    Kanehiro, H
    Horikawa, M
    Yoshimura, A
    Kido, K
    Taki, J
    Aomatsu, Y
    Kin, T
    Yagura, K
    Ohyama, T
    Ohashi, K
    Yamada, T
    Nakano, H
    TRANSPLANTATION PROCEEDINGS, 1996, 28 (02) : 1066 - 1068
  • [7] EARLY TRIALS WITH FK-506 AS PRIMARY-TREATMENT IN LIVER-TRANSPLANTATION
    TODO, S
    FUNG, JJ
    DEMETRIS, AJ
    JAIN, A
    VENKATARAMANAN, R
    STARZL, TE
    TRANSPLANTATION PROCEEDINGS, 1990, 22 (01) : 13 - 16
  • [8] FK-506 ASSOCIATED DISORDERS IN LIVER-TRANSPLANTATION
    NAZER, H
    ALSABBAN, E
    HARFI, H
    ANTONIUS, J
    DACUNHA, AM
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1992, 7 (03) : 257 - 259
  • [9] Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation
    Samuel, D
    Bismuth, H
    Boillot, O
    Ducerf, C
    Baulieux, J
    Gugenheim, J
    Baldini, E
    Launois, B
    Messner, M
    Wolf, P
    Ellero, E
    Domergue, J
    Pageaux, J
    Cherqui, D
    Duvoux, C
    Durand, F
    Belghiti, J
    Calmus, Y
    Massault, PP
    Neau-Cransac, M
    Saric, J
    LeTreut, Y
    Campan, P
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) : 1394 - 1396
  • [10] Conversion of liver allograft recipients from cyclosporine A to FK 506 immunosuppressive therapy
    Ben-Ari, Z
    Mor, E
    Shaharabani, E
    Bar-Nathan, N
    Shapira, Z
    Tur-Kaspa, R
    TRANSPLANTATION PROCEEDINGS, 2000, 32 (04) : 709 - 710
12345